Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma.
|
29373711 |
2018 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer.
|
28008156 |
2017 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TIMP1, HMGB3, CLDN1, CDK1 and PPARG as well as pathways of Cell cycle, Citrate cycle, and Oxidative phosphorylation may play important roles in the progression of thyroid carcinoma.
|
27268919 |
2016 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared with RAS or PAX8/PPARG-positive TCs, BRAFV600E or RET/PTC-positive TCs were more often associated with stage III/IV disease (40% vs 15%, P < 0.001) and recurrence (10% vs 0.7%, P < 0.001; mean follow-up 33 ± 21 mo).
|
26258321 |
2015 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall.
|
24811481 |
2014 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PPAR-γ agonist pioglitazone is highly therapeutic in a transgenic mouse model of PPFP-positive thyroid carcinoma, suggesting that PPAR-γ agonists might be beneficial in patients with PPFP-positive thyroid carcinomas.
|
25069464 |
2014 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics.
|
23436219 |
2013 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TSH receptor mRNA reverse transcription-polymerase chain reaction, the Veracyte and Asuragen commercial methods, and the noncommercial use of BRAF, RAS, RET/PTC, and PAX8/PPARγ testing have promising roles in the diagnosis and treatment of patients with nodular thyroid disease and thyroid cancer.
|
22984796 |
2013 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases.
|
23738683 |
2013 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements.
|
21878896 |
2011 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs).
|
19147628 |
2009 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As such, this article addresses the following aspects of intragenic mutations in thyroid cancer: thyroid stimulating hormone receptor and guanine-nucleotide-binding proteins of the stimulatory family mutations in hyperfunctioning tumors; mutations in RAS and other genes and aneuploidy; PAX8-PPARgamma rearrangements; BRAF mutations; mutations in oxidative phosphorylation and Krebs cycle genes in Hürthle cell tumors; mutations in succinate dehydrogenase genes in medullary carcinoma and C-cell hyperplasia; and mutations in TP53 and other genes in poorly differentiated and anaplastic carcinomas.
|
18502330 |
2008 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we report our discovery of a novel CREB3L2-PPARgamma fusion mutation in thyroid carcinoma with t(3;7)(p25;q34), showing that a family of somatic PPARgamma fusion mutations exist in thyroid cancer.
|
18757431 |
2008 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The common somatic genetic changes in thyroid cancer of follicular cell origin (RET/PTC, NTRK, RAS, BRAF, PAX8-PPARgamma) are generally mutually exclusive, with distinct genotype-histologic subtype of thyroid cancer and genotype-phenotype associations observed.
|
18043251 |
2008 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using this mutant mouse, we tested the hypothesis that the peroxisome proliferator-activated receptor gamma (PPARgamma) could function as a tumor suppressor in thyroid cancer in vivo.
|
16314832 |
2006 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rosiglitazone is a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist that has been shown to induce differentiation, cell cycle arrest, and apoptosis in a variety of human cancers including thyroid cancer.
|
17188145 |
2006 |
Thyroid carcinoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Our investigations document that human thyroid cancer cell lines commonly express PPARgamma, but chromosomal translocations involving PPARgamma are uncommon.
|
15785241 |
2005 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our investigations document that human thyroid cancer cell lines commonly express PPARgamma, but chromosomal translocations involving PPARgamma are uncommon.
|
15785241 |
2005 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data identify several differentially expressed genes, such as FGD3, that may serve as potential targets of PPARgamma and as members of novel molecular pathways involved in the development of thyroid carcinomas.
|
15972966 |
2005 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Absence of a PAX-8/PPAR-gamma fusion gene in the series of 68 thyroid samples is in agreement with the suggestion of PAX-8/PPAR-gamma rearrangement being restricted to a subset of follicular thyroid cancers.
|
16187907 |
2005 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objectives of the present work were: to study and compare the relative expression of PPARgamma in normal, benign and malignant thyroid tissues and to correlate PPARgamma immunostaining with clinical/pathological features of patients with thyroid cancer.
|
15238980 |
2004 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that PPARgamma agonist inhibit cell growth of some types of human thyroid cancer.
|
11344222 |
2001 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The experiments demonstrate an oncogenic role for PPARgamma and suggest that PAX8-PPARgamma1 may be useful in the diagnosis and treatment of thyroid carcinoma.
|
10958784 |
2000 |